Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With PBRM1, SETD2, BAP1, or KDM5C Mutations

被引:5
|
作者
Liu, Yang [1 ]
Li, Yunhao [2 ]
Xu, Haimin [1 ]
Zhou, Luting [1 ,3 ]
Yang, Xiaoqun [1 ,3 ]
Wang, Chaofu [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China
[2] China Med Univ, Clin Coll 1, Shenyang, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Pathol, Number197,Ruijin Er Rd, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; PBRM1; BAP1; KDM5C; SETD2; morphology;
D O I
10.1177/10668969231157317
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The last decade has seen great advances in genomic profiling and prognosis-associated factors of clear cell renal cell carcinoma (RCC), the most common entity in kidney cancer. Following VHL, PBRM1, SETD2, BAP1, and KDM5C have been validated as the most common co-occurring gene mutations in clear cell RCC by multicenter studies. However, the morphological features of clear cell RCC with co-occurring gene mutations remain unclear. In this study, we presented 20 clear cell RCCs that underwent next-generation sequencing, of which 1 tumor was reclassified as ELOC-mutated RCC. PBRM1, SETD2, BAP1, and KDM5C were the most common mutations, following VHL. Morphologically, clear cell RCC with PBRM1 or KDM5C mutation usually displayed a low-grade pattern. Cystic changes and hyalinized stroma were often observed. The Ki67 index was <10%. These observations indicated good prognosis. However, mutated SETD2 may increase the malignancy of clear cell RCC with PBRM1 mutation. Two clear cell RCCs with mutated PBRM1 and SETD2 developed local or distant metastases. Clear cell RCC with BAP1 mutations always had high-grade patterns, and rhabdoid differentiation was also observed, indicating that BAP1 mutation was associated with poor outcomes. Papillary architecture was often a feature of BAP1 mutation, which is uncommon in clear cell RCC. PDL1 was positive in only one tumor with BAP1 mutation, and the positivity rate was limited to 5%. B7H3 was negative in all tumors. Morphologic findings in this small cohort may suggest why PBRM1 mutation does not correlate with decreased survival, whereas BAP1 mutation usually predicts poor outcomes.
引用
收藏
页码:1485 / 1494
页数:10
相关论文
共 50 条
  • [21] Concomitant Loss of PBRM1 and BAP1 Protein Expression is an Important Prognostic Event in Early Stages of Clear Cell Renal Cell Carcinoma.
    da Cunha, Isabela W.
    da Costa, Walter H.
    Fares, Aline F.
    Bezerra, Stephania M.
    Schultz, Luciana
    Guimaraes, Gustavo C.
    Zequi, Stenio C.
    MODERN PATHOLOGY, 2018, 31 : 336 - 336
  • [22] PBRM1 but not BAP1 deficiency is a frequent feature of multifocal non-cystic low-grade clear cell renal cell carcinoma
    Agaimy, Abbas
    Trpkov, Kiril
    Gao, Yuan
    Hartmann, Arndt
    Hes, Ondrej
    LABORATORY INVESTIGATION, 2019, 99
  • [23] PBRM1 but not BAP1 deficiency is a frequent feature of multifocal non-cystic low-grade clear cell renal cell carcinoma
    Agaimy, Abbas
    Trpkov, Kiril
    Gao, Yuan
    Hartmann, Arndt
    Hes, Ondrej
    MODERN PATHOLOGY, 2019, 32
  • [24] Expression of Bap1 in Clear Cell Renal Cell Carcinoma
    Fatima, Arooj
    JOURNAL OF PATHOLOGY, 2024, 264 : S12 - S12
  • [25] Functional role of SETD2, BAP1, PARP-3 and PBRM1 candidate genes on the regulation of hTERT gene expression
    Linne, Hannah
    Yasaei, Hemad
    Marriott, Alison
    Harvey, Amanda
    Mokbel, Kefah
    Newbold, Robert
    Roberts, Terry
    ONCOTARGET, 2017, 8 (37) : 61890 - 61900
  • [26] Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
    Carril-Ajuria, Lucia
    Santos, Maria
    Maria Roldan-Romero, Juan
    Rodriguez-Antona, Cristina
    de Velasco, Guillermo
    CANCERS, 2020, 12 (01)
  • [27] VHL, PBRM1, and BAP1 mutation variants and response to first-line therapies in patients with metastatic clear-cell renal cell carcinoma (mRCC)
    Zhu, Jessica
    Hu, Junxiao
    Lam, Elaine T.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [28] KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells
    Mueller, Marvin
    Zodel, Kyra
    Abhari, Behnaz A.
    Cuomo, Francesca
    Nizamuddin, Sheikh
    Metzger, Patrick
    Boerries, Melanie
    Timmers, H. T. Marc
    Frew, Ian J.
    COMMUNICATIONS BIOLOGY, 2025, 8 (01)
  • [29] The expanding role of BAP1 in clear cell renal cell carcinoma
    Kapur, Payal
    Rajaram, Satwik
    Brugarolas, James
    HUMAN PATHOLOGY, 2023, 133 : 22 - 31
  • [30] Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
    Aili, Abudureyimujiang
    Wen, Jie
    Xue, Lixiang
    Wang, Junjie
    FRONTIERS IN ONCOLOGY, 2021, 11